Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

AIOCC Italian Registry on Head and Neck Carcinomas

NCT06248944 · tracked via the Priya Life Science Italy tracker
Sponsor
Italian Head&Neck Society
Phase
Observational
Started
2022-07-06
Last updated
2024-03-08

Condition(s) studied

Head and Neck Carcinoma

Investigational drug(s) / intervention(s)

observational-retrospective and prospective

observational-retrospective and prospective: observational-retrospective and prospective

Study summary

Multicentre, retrospective and prospective observational study aimed to set-up a clinical Italian registry in order to collect information on carcinoma of the Head and Neck.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adult patients (age ≥ 18 years old) diagnosed with carcinoma of the Head and Neck. The diagnosis should be done or verified by the expert site entering the information about the patient in the registry. Patients diagnosed with sarcomas and lymphomas are excluded. 2. Patients entering the HCP at any clinical phase of the disease (diagnosis, treatment of primary cancer, treatment of recurrence, treatment of M+ etc.). The HCP will collect information on the entire disease regardless of when it started to manage the patient. The HCP can choose, based on its resources, for how many patients will be able to collect the data. 3. New patients managed by the HCP from 2021 onwards + patients managed by the HCP, in active follow-up at the hospital Exclusion Criteria: 1\. Patients whose medical records are unavailable for review

Primary outcome measure(s)

  • types of diagnostic and treatment patterns — From the enrollment to the end of the study (5 years)
    To document types of diagnostic and treatment patterns by all stages of disease and frequency, and proportion with which they are used in the different stages of Head and Neck cancer.

Trial sites (7)

FacilityCityRegionStatus
Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo Italy Recruiting
A.O.U. Careggi Florence Italy Recruiting
P.O. 'Vito Fazzi' Lecce Italy Recruiting
Fondazione IRCCS Istituto Nazionale Tumori Milan Italy Recruiting
Fondazione CNAO Pavia Italy Recruiting
Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS Roma Italy Recruiting
Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06248944 on ClinicalTrials.gov ↗ ← All trials in Italy